{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:15:09Z","timestamp":1790889309082,"version":"4.1.0"},"reference-count":33,"publisher":"The Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>The aim was to perform a first comparison between the effects of a classic therapy and those of a novel treatment for androgen excess in adolescent girls.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design and Setting:<\/jats:title>\n                  <jats:p>We conducted a randomized, open-labeled trial at a university hospital.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants:<\/jats:title>\n                  <jats:p>Thirty-four adolescents with hyperinsulinemic androgen excess and without risk of pregnancy participated in the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions:<\/jats:title>\n                  <jats:p>Ethinyl estradiol-cyproterone acetate (EE-CA) vs. a low-dose combination of pioglitazone, flutamide, and metformin (PioFluMet) was administered for 6 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures:<\/jats:title>\n                  <jats:p>We assessed hirsutism and acne scores; androgen excess; fasting insulin, lipid profile, C-reactive protein, high molecular-weight adiponectin, leptin, follistatin; carotid intima-media thickness; body composition (absorptiometry); and abdominal fat partitioning (magnetic resonance imaging).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>EE-CA and PioFluMet attenuated the androgen excess comparably but had divergent effects on fasting insulinemia; on circulating cholesterol, triglycerides, C-reactive protein, high molecular-weight adiponectin, leptin, and follistatin; on carotid intima-media thickness; on lean mass; and on abdominal, visceral, and hepatic fat, with all these divergences pointing to a healthier condition on low-dose PioFluMet.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>Low-dose PioFluMet compared favorably to EE-CA in adolescents with androgen excess and without pregnancy risk. The efficacy and safety of low-dose PioFluMet remain to be studied over a longer term and in larger cohorts.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2011-1671","type":"journal-article","created":{"date-parts":[[2011,8,25]],"date-time":"2011-08-25T03:34:08Z","timestamp":1314243248000},"page":"3361-3366","source":"Crossref","is-referenced-by-count":35,"title":["Treatment of Androgen Excess in Adolescent Girls: Ethinylestradiol-Cyproteroneacetate Versus Low-Dose Pioglitazone-Flutamide-Metformin"],"prefix":"10.1210","volume":"96","author":[{"given":"Lourdes","family":"Ib\u00e1\u00f1ez","sequence":"first","affiliation":[{"name":"Endocrinology Unit (L.I., M.D., G.S., D.S.-I.), Hospital Sant Joan de D\u00e9u, University of Barcelona, 08950 Esplugues, Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Diabetes y Enfermedades Metab\u00f3licas Asociadas (L.I., M.D., G.S., D.S.-I.), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Diaz","sequence":"additional","affiliation":[{"name":"Endocrinology Unit (L.I., M.D., G.S., D.S.-I.), Hospital Sant Joan de D\u00e9u, University of Barcelona, 08950 Esplugues, Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Diabetes y Enfermedades Metab\u00f3licas Asociadas (L.I., M.D., G.S., D.S.-I.), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Sebastiani","sequence":"additional","affiliation":[{"name":"Endocrinology Unit (L.I., M.D., G.S., D.S.-I.), Hospital Sant Joan de D\u00e9u, University of Barcelona, 08950 Esplugues, Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Diabetes y Enfermedades Metab\u00f3licas Asociadas (L.I., M.D., G.S., D.S.-I.), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"S\u00e1nchez-Infantes","sequence":"additional","affiliation":[{"name":"Endocrinology Unit (L.I., M.D., G.S., D.S.-I.), Hospital Sant Joan de D\u00e9u, University of Barcelona, 08950 Esplugues, Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Diabetes y Enfermedades Metab\u00f3licas Asociadas (L.I., M.D., G.S., D.S.-I.), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Salvador","sequence":"additional","affiliation":[{"name":"Gynecology Department (C.S.), Hospital Sant Joan de D\u00e9u, University of Barcelona, 08950 Esplugues, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Lopez-Bermejo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (A.L.-B.), Dr. Josep Trueta Hospital, and Girona Institute for Biomedical Research, 17007 Girona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"de Zegher","sequence":"additional","affiliation":[{"name":"University of Leuven (F.d.Z.), 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071616144892600_B1","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMra041536","article-title":"Polycystic ovary syndrome.","volume":"352","author":"Ehrmann","year":"2005","journal-title":"N Engl J Med"},{"key":"2020071616144892600_B2","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1056\/NEJMcp033496","article-title":"Hirsutism.","volume":"353","author":"Rosenfield","year":"2005","journal-title":"N Engl J Med"},{"key":"2020071616144892600_B3","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1210\/jc.2007-2437","article-title":"Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline.","volume":"93","author":"Martin","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(07)61345-2","article-title":"Polycystic ovary syndrome.","volume":"370","author":"Norman","year":"2007","journal-title":"Lancet"},{"key":"2020071616144892600_B5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/humrep\/dem379","article-title":"Cyproterone acetate\/ethinyl oestradiol for acne and hirsutism: time to revise prescribing policy.","volume":"23","author":"Franks","year":"2008","journal-title":"Hum Reprod"},{"key":"2020071616144892600_B6","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/jc.2007-0282","article-title":"Comparison of ethinyl-oestradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.","volume":"92","author":"Luque-Ram\u00edrez","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.tem.2009.06.003","article-title":"Adipose tissue expandability and the early origins of PCOS.","volume":"20","author":"de Zegher","year":"2009","journal-title":"Trends Endocrinol Metab"},{"key":"2020071616144892600_B8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1210\/jcem-50-1-113","article-title":"Correlation of hyperandrogenism with hyperinsulinaemia in polycystic ovarian disease.","volume":"50","author":"Burghen","year":"1980","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B9","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1210\/jcem-57-2-356","article-title":"Insulin resistance in nonobese patients with polycystic ovarian disease.","volume":"57","author":"Chang","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0015-0282(16)60060-2","article-title":"The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism.","volume":"50","author":"Barbieri","year":"1988","journal-title":"Fertil Steril"},{"key":"2020071616144892600_B11","first-page":"774","article-title":"Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.","volume":"18","author":"Dunaif","year":"1997","journal-title":"Endocr Rev"},{"key":"2020071616144892600_B12","doi-asserted-by":"crossref","first-page":"E304","DOI":"10.1210\/jc.2010-1290","article-title":"Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance.","volume":"96","author":"Manner\u00e5s-Holm","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B13","doi-asserted-by":"crossref","first-page":"E1262","DOI":"10.1210\/jc.2011-0555","article-title":"Early metformin therapy (age 8\u201312 yr) in girls with precocious pubarche to reduce hirsutism, androgen excess and oligomenorrhea in adolescence.","volume":"96","author":"Ib\u00e1\u00f1ez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B14","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1210\/jc.2006-2684","article-title":"Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess.","volume":"92","author":"Ib\u00e1\u00f1ez","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2265.2007.03137.x","article-title":"Pioglitazone (7.5 mg\/d) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high-molecular-weight adiponectin.","volume":"68","author":"Ib\u00e1\u00f1ez","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616144892600_B16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2265.2008.03472.x","article-title":"Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months.","volume":"71","author":"Ib\u00e1\u00f1ez","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616144892600_B17","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3109\/09513590.2010.487589","article-title":"Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months.","volume":"26","author":"Ib\u00e1\u00f1ez","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"2020071616144892600_B18","first-page":"1237","article-title":"Hyperinsulinemia in postpubertal girls with a history of premature pubarche and functional ovarian hyperandrogenism.","volume":"81","author":"Ib\u00e1\u00f1ez","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B19","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1210\/jc.2003-031281","article-title":"Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.","volume":"89","author":"Ib\u00e1\u00f1ez","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B20","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1210\/jc.2008-2005","article-title":"Role of follistatin in promoting adipogenesis in women.","volume":"94","author":"Flanagan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/humupd\/dmi054","article-title":"Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women.","volume":"12","author":"Ib\u00e1\u00f1ez","year":"2006","journal-title":"Hum Reprod Update"},{"key":"2020071616144892600_B22","first-page":"3526","article-title":"Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidaemia, and hyperinsulinism after precocious pubarche.","volume":"85","author":"Ib\u00e1\u00f1ez","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B23","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1210\/jcem.86.8.7756","article-title":"Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism.","volume":"86","author":"Ib\u00e1\u00f1ez","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B24","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1210\/jcem.87.6.8568","article-title":"Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation.","volume":"87","author":"Ib\u00e1\u00f1ez","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B25","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1210\/jc.2002-022002","article-title":"Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism.","volume":"88","author":"Ib\u00e1\u00f1ez","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B26","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1210\/jc.2004-0047","article-title":"Flutamide-metformin plus ethinyloestradiol-drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.","volume":"89","author":"Ib\u00e1\u00f1ez","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1210\/jc.2004-1405","article-title":"Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at start and after more than one year of therapy.","volume":"90","author":"Ib\u00e1\u00f1ez","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrendo.2010.119","article-title":"Low-dose flutamide for hirsutism: into the limelight, at last.","volume":"6","author":"de Zegher","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"2020071616144892600_B29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR\u03b3 by Cdk5.","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"key":"2020071616144892600_B30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm.2349","article-title":"A role for central nervous system PPAR-\u03b3 in the regulation of energy balance.","volume":"17","author":"Ryan","year":"2011","journal-title":"Nat Med"},{"key":"2020071616144892600_B31","doi-asserted-by":"crossref","first-page":"18073","DOI":"10.1074\/jbc.M414231200","article-title":"Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes.","volume":"280","author":"Xu","year":"2005","journal-title":"J Biol Chem"},{"key":"2020071616144892600_B32","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1210\/jc.2009-1557","article-title":"High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance.","volume":"95","author":"O'Connor","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144892600_B33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1530\/EJE-10-0021","article-title":"Distribution of adiponectin multimeric forms in Chinese women with polycystic ovary syndrome and their relation to insulin resistance.","volume":"163","author":"Tao","year":"2010","journal-title":"Eur J Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/96\/11\/3361\/9087184\/jcem3361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/96\/11\/3361\/9087184\/jcem3361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:12:26Z","timestamp":1594955546000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/96\/11\/3361\/2834334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,1]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2011-1671","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,1]]}}}